GCCR
MCID: GLC037
MIFTS: 62

Glucocorticoid Resistance (GCCR) malady

Categories: Genetic diseases, Rare diseases, Reproductive diseases, Endocrine diseases, Fetal diseases

Aliases & Classifications for Glucocorticoid Resistance

Aliases & Descriptions for Glucocorticoid Resistance:

Name: Glucocorticoid Resistance 54 50 24 56 66
Cortisol Resistance from Glucocorticoid Receptor Defect 50 24 66
Glucocorticoid Resistance, Generalized 54 66 29
Glucocorticoid Receptor Deficiency 24 66 69
Cortisol Resistance 66 13
Gccr Deficiency 24 66
Gcr Deficiency 24 66
Grl Deficiency 24 66
Gccr 24 66
Chrousos Syndrome 66
Gcres 66

Characteristics:

Orphanet epidemiological data:

56
glucocorticoid resistance
Inheritance: Autosomal dominant,Autosomal recessive,Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

HPO:

32
glucocorticoid resistance:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 615962
Orphanet 56 ORPHA786
ICD10 via Orphanet 34 E25.8
MeSH 42 D008661

Summaries for Glucocorticoid Resistance

OMIM : 54 Generalized glucocorticoid resistance is an autosomal dominant disease characterized by increased plasma cortisol... (615962) more...

MalaCards based summary : Glucocorticoid Resistance, also known as cortisol resistance from glucocorticoid receptor defect, is related to hepatitis and leukemia, and has symptoms including fatigue, hypertension and precocious puberty. An important gene associated with Glucocorticoid Resistance is NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Th17 cell differentiation. The drugs Prednisone and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and testes, and related phenotypes are Increased transferrin (TF) endocytosis and Synthetic lethal with MLN4924 (a NAE inhibitor)

UniProtKB/Swiss-Prot : 66 Glucocorticoid resistance: Hypertensive, hyperandrogenic disorder characterized by increased serum cortisol concentrations. Inheritance is autosomal dominant. Glucocorticoid resistance, generalized: An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety.

Related Diseases for Glucocorticoid Resistance

Diseases related to Glucocorticoid Resistance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
id Related Disease Score Top Affiliating Genes
1 hepatitis 29.6 IL10 IL2
2 leukemia 10.3
3 lymphoblastic leukemia 10.2
4 subacute monocytic leukemia 10.1 BCL2 NR3C1
5 acute allergic sanguinous otitis media 10.1 BCL2 IL2
6 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.1 IL10 IL2
7 primary tubular proximal acidosis 10.1 BCL2 IL2
8 hypoaldosteronism, congenital, due to cmo i deficiency 10.1 NR3C1 NR3C2
9 plantar wart 10.1 IL10 IL2
10 cyclosporiasis 10.1 IL10 IL2
11 chronic thromboembolic pulmonary hypertension 10.1 IL10 IL2
12 tularemia 10.1 IL10 IL2
13 cataract 21, multiple types 10.1 NR3C1 NR3C2
14 hypoglycemic coma 10.1 IL2 NR3C1
15 cerebellar liponeurocytoma 10.1 BCL2 IL2
16 merkel cell carcinoma 10.1 NR3C1 NR3C2
17 esophagus squamous cell papilloma 10.1 NR3C1 NR3C2
18 acute myeloid leukemia with recurrent genetic anomaly 10.1 IL10 IL2
19 microcephaly 10.0 IL10 IL2
20 abnormal retinal correspondence 10.0 IL10 IL2
21 asthma 10.0
22 rhabdomyosarcoma 10.0 IL10 IL2
23 lichen disease 10.0 IL10 IL2 NR3C1
24 lung combined large cell neuroendocrine carcinoma 10.0 IL10 IL2
25 tuberculosis 10.0 IL10 IL2
26 oropharynx cancer 9.9 IL10 IL2
27 pulmonary fibrosis, idiopathic 9.9 BCL2 IL10 IL2
28 orbital osteomyelitis 9.9 IL10 IL2
29 arthritis 9.8
30 rheumatoid arthritis 9.8
31 thrombocytopenia 9.7
32 ulcerative colitis 9.7
33 inflammatory bowel disease 9.7
34 colitis 9.7
35 childhood leukemia 9.7
36 splenic tuberculosis 9.6 FKBP5 FOS NR3C1 NR3C2
37 multiple myeloma 9.6
38 acute lymphocytic leukemia 9.6
39 nephrotic syndrome 9.6
40 chronic lymphocytic leukemia 9.6
41 crohn's disease 9.6
42 systemic lupus erythematosus 9.6
43 lupus erythematosus 9.6
44 breast cancer 9.5
45 chronic leukemia 9.5
46 evans' syndrome 9.5
47 obesity 9.5
48 allergic encephalomyelitis 9.5
49 hyperandrogenism 9.5
50 growth hormone deficiency 9.5

Graphical network of the top 20 diseases related to Glucocorticoid Resistance:



Diseases related to Glucocorticoid Resistance

Symptoms & Phenotypes for Glucocorticoid Resistance

Symptoms by clinical synopsis from OMIM:

615962

Clinical features from OMIM:

615962

Human phenotypes related to Glucocorticoid Resistance:

56 32 (show all 26)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 56 32 Very frequent (99-80%) HP:0012378
2 hypertension 56 32 Frequent (79-30%) HP:0000822
3 precocious puberty 56 32 Occasional (29-5%) HP:0000826
4 hypokalemia 56 32 Frequent (79-30%) HP:0002900
5 hypoglycemia 56 32 Occasional (29-5%) HP:0001943
6 acne 56 32 Frequent (79-30%) HP:0001061
7 increased urinary cortisol level 56 32 Very frequent (99-80%) HP:0012030
8 stroke 56 32 Very rare (<4-1%) HP:0001297
9 female pseudohermaphroditism 56 32 Occasional (29-5%) HP:0010458
10 ambiguous genitalia 56 32 Occasional (29-5%) HP:0000062
11 infertility 56 32 Occasional (29-5%) HP:0000789
12 oligospermia 56 32 Occasional (29-5%) HP:0000798
13 decreased circulating aldosterone level 56 32 Very frequent (99-80%) HP:0004319
14 increased circulating acth level 56 32 Very frequent (99-80%) HP:0003154
15 increased circulating cortisol level 56 32 Very frequent (99-80%) HP:0003118
16 adrenal hyperplasia 56 32 Frequent (79-30%) HP:0008221
17 hirsutism 56 32 Very frequent (99-80%) HP:0001007
18 frontal balding 56 32 Occasional (29-5%) HP:0002292
19 metabolic alkalosis 56 32 Frequent (79-30%) HP:0200114
20 oligomenorrhea 56 32 Frequent (79-30%) HP:0000876
21 anxiety 32 HP:0000739
22 hypercortisolism 56 Occasional (29-5%)
23 menstrual irregularities 32 HP:0000858
24 abnormal testosterone level 56 Frequent (79-30%)
25 hypokalemic alkalosis 32 HP:0001949
26 abnormal serum testosterone level 32 HP:0030087

UMLS symptoms related to Glucocorticoid Resistance:


fatigue

GenomeRNAi Phenotypes related to Glucocorticoid Resistance according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased transferrin (TF) endocytosis GR00363-A 9.5 NR3C1 NR3C2 BCL2A1 FKBP5 FOS IL10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 BCL2 FKBP5 IL10 IL2
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 BCL2 BCL2A1 FKBP5 IL10 IL2

MGI Mouse Phenotypes related to Glucocorticoid Resistance:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.87 BCL2 FKBP5 FOS IL10 IL2 NR3C1
2 hematopoietic system MP:0005397 9.73 BCL2 FOS IL10 IL2 NR3C1 NR3C2
3 homeostasis/metabolism MP:0005376 9.7 BCL2 FKBP5 FOS IL10 IL2 NR3C1
4 mortality/aging MP:0010768 9.5 BCL2 FKBP5 FOS IL10 IL2 NR3C1
5 reproductive system MP:0005389 9.1 FKBP5 FOS IL10 IL2 NR3C1 BCL2

Drugs & Therapeutics for Glucocorticoid Resistance

Drugs for Glucocorticoid Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 497)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
2
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3 169590-42-5 2662
3 Parecoxib Approved Phase 4 198470-84-7
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
5
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1 51333-22-3 63006 5281004
6
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3, 179045-86-4
7
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
8
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 83-43-2 6741
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
11
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
12
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
13
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-24-8 5755
14
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
16
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 179324-69-7 387447 93860
17
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
18
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
19
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
20
Mifepristone Approved, Investigational Phase 4,Phase 2,Phase 1 84371-65-3 55245
21
Cycloserine Approved Phase 4 68-41-7 401 6234
22
Ciprofloxacin Approved, Investigational Phase 4,Phase 3 85721-33-1 2764
23
Lenograstim Approved Phase 4,Phase 2,Phase 1 135968-09-1
24
Bisoprolol Approved Phase 4 66722-44-9 2405
25
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
26
Diphenhydramine Approved Phase 4,Phase 2 58-73-1, 147-24-0 3100
27
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
28
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
29
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
30
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
31
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
32
Promethazine Approved Phase 4,Phase 2 60-87-7 4927
33
Ranitidine Approved Phase 4,Phase 1 66357-59-3, 66357-35-5 3001055
34
Montelukast Approved Phase 4 158966-92-8 5281040
35
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
36
Melphalan Approved Phase 4,Phase 2 148-82-3 4053 460612
37
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
38
Adenosine Approved, Investigational Phase 4 58-61-7 60961
39
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
40
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
41
Metronidazole Approved Phase 4,Phase 2 443-48-1 4173
42
Desoximetasone Approved Phase 4 382-67-2 5311067
43
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
44
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
45
Vancomycin Approved Phase 4 1404-90-6 441141 14969
46
Betamethasone Approved, Vet_approved Phase 4,Phase 3 378-44-9 9782
47
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
48
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
49
Itraconazole Approved, Investigational Phase 4,Phase 1,Phase 2 84625-61-6 55283
50
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453

Interventional clinical trials:

(show top 50) (show all 320)
id Name Status NCT ID Phase
1 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4
2 Vitamin D for the Treatment of Severe Asthma Unknown status NCT00712205 Phase 4
3 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4
4 Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Unknown status NCT00867737 Phase 4
5 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4
6 Optimal Treatment of Plantar Fasciitis: Physical Training, Glucocorticoid Injections or a Combination Thereof. Completed NCT01994759 Phase 4
7 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism Completed NCT01990560 Phase 4
8 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4
9 Developing Memory Reconsolidation Blockers as Novel Post-traumatic Stress Disorder (PTSD) Treatments Completed NCT01490697 Phase 4
10 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4
11 Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients. Completed NCT01329276 Phase 4
12 Dose-Response of Salmeterol in Children Completed NCT01907334 Phase 4
13 Chronic Obstructive Pulmonary Disease Endpoints Study Completed NCT00358358 Phase 4
14 Beta Blocker Therapy in Moderate to Severe COPD Completed NCT01656005 Phase 4
15 Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies. Completed NCT00370591 Phase 4
16 Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Asthmatic Patients Completed NCT00910793 Phase 4
17 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4
18 Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00202189 Phase 4
19 Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing Completed NCT02381158 Phase 4
20 Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma Completed NCT00490243 Phase 4
21 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4
22 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4
23 Efficacy Study of Local Steroid Injection and Wrist Splinting for Carpal Tunnel Syndrome Completed NCT02140632 Phase 4
24 Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation Completed NCT00717379 Phase 4
25 Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD Completed NCT00489853 Phase 4
26 A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects Completed NCT01751113 Phase 4
27 Effects of QVAR in Smokers With Asthma Completed NCT01741285 Phase 4
28 Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation Completed NCT00724022 Phase 4
29 Achilles Tendinopathy Treated With Training and Injections Recruiting NCT02580630 Phase 4
30 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4
31 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4
32 Evaluating Treatment Resistant Dermatitis TaroIIR Recruiting NCT03050294 Phase 4
33 A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy Recruiting NCT02405858 Phase 4
34 Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS Recruiting NCT02344888 Phase 4
35 Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Recruiting NCT02485691 Phase 4
36 Manipulating the Microbiome in IBD by Antibiotics and FMT Recruiting NCT02033408 Phase 4
37 Effect of Antenatal Steroid on Pulmonary Artery Blood Flow Recruiting NCT02978976 Phase 4
38 Small Airways Evaluation and Treatment Recruiting NCT02526758 Phase 4
39 Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Recruiting NCT03016741 Phase 4
40 Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients Active, not recruiting NCT01995513 Phase 4
41 Effects Of Adjuvants to Caudal Anesthesia on Hemodynamics Measured By Electrical Cardiometry In Children Enrolling by invitation NCT03101137 Phase 4
42 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4
43 ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Grou Terminated NCT00346749 Phase 4
44 No Resistance After Long Term Treatment SERETIDE Withdrawn NCT00456313 Phase 4
45 Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer Withdrawn NCT01692483 Phase 4
46 Prevention of Metabolic Complications of Glucocorticoid Excess Unknown status NCT01319994 Phase 2, Phase 3
47 Steroids in Patients With Early ARDS Unknown status NCT00562835 Phase 2, Phase 3
48 Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies Completed NCT02662400 Phase 2, Phase 3
49 Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis Completed NCT00420251 Phase 3
50 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 Completed NCT01605227 Phase 3

Search NIH Clinical Center for Glucocorticoid Resistance

Genetic Tests for Glucocorticoid Resistance

Genetic tests related to Glucocorticoid Resistance:

id Genetic test Affiliating Genes
1 Glucocorticoid Resistance, Generalized 29
2 Glucocorticoid Resistance 24 NR3C1

Anatomical Context for Glucocorticoid Resistance

MalaCards organs/tissues related to Glucocorticoid Resistance:

39
T Cells, B Cells, Testes, Skin, Kidney, Breast, Brain

Publications for Glucocorticoid Resistance

Articles related to Glucocorticoid Resistance:

(show top 50) (show all 252)
id Title Authors Year
1
Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia. ( 28415682 )
2017
2
Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. ( 28479211 )
2017
3
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. ( 28484265 )
2017
4
Mechanisms of Brain Glucocorticoid Resistance in Stress-Induced Psychopathologies. ( 28320277 )
2017
5
Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia. ( 27798768 )
2017
6
Glucocorticoid resistance as a major drive in sepsis pathology. ( 28479044 )
2017
7
Glucocorticoid resistance of migration and gene expression in a daughter MDA-MB-231 breast tumour cell line selected for high metastatic potential. ( 28262792 )
2017
8
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. ( 27579615 )
2016
9
Cytokine-Induced Glucocorticoid Resistance from Eosinophil Activation: Protein Phosphatase 5 Modulation of Glucocorticoid Receptor Phosphorylation and Signaling. ( 27742828 )
2016
10
Three Novel Heterozygous Point Mutations of NR3C1 causing Glucocorticoid Resistance. ( 27120390 )
2016
11
Recent advances in the molecular mechanisms causing primary generalized glucocorticoid resistance. ( 27086682 )
2016
12
Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis. ( 27869314 )
2016
13
Relationship between expression of glucocorticoid receptor isoforms and glucocorticoid resistance in immune thrombocytopenia. ( 27077774 )
2016
14
Inflammasome-mediated glucocorticoid resistance: The receptor rheostat. ( 27308575 )
2016
15
Glucocorticoid resistance syndrome caused by two novel mutations in the NR3C1 gene. ( 27211791 )
2016
16
Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance. ( 27001230 )
2016
17
Prenatal SSRI alters the hormonal and behavioral responses to stress in female mice: Possible role for glucocorticoid resistance. ( 27283378 )
2016
18
Glucocorticoid resistance in chronic diseases. ( 27643454 )
2016
19
Testicular Receptor-4: Novel Regulator of Glucocorticoid Resistance. ( 27253665 )
2016
20
Altered expression of autophagy-related genes might contribute to glucocorticoid resistance in precursor B-cell type acute lymphoblastic leukemia. ( 26947147 )
2016
21
NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. ( 25938942 )
2015
22
An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance. ( 25503867 )
2015
23
Changes of glucocorticoid receptor isoforms expression in acute lymphoblastic leukemia correlate with glucocorticoid resistance. ( 26062300 )
2015
24
MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. ( 26324703 )
2015
25
Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines. ( 25985447 )
2015
26
Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. ( 26713593 )
2015
27
Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition. ( 26310606 )
2015
28
Inhibition of autophagy overcomes glucocorticoid resistance in lymphoid malignant cells. ( 25778879 )
2015
29
Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts. ( 25967739 )
2015
30
Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance. ( 25735983 )
2015
31
Influence of glucocorticoid receptor gene NR3C1 646 C>G polymorphism on glucocorticoid resistance in asthmatics: a preliminary study. ( 26648776 )
2015
32
Glucocorticoid receptor polymorphisms: Lack of association with glucocorticoid resistance among Chinese bullous disease patients. ( 25894104 )
2015
33
Another step in understanding glucocorticoid resistance in critical illness. ( 26039432 )
2015
34
The NLRP3-CASP1 Inflammasome Induces Glucocorticoid Resistance in ALL. ( 25977218 )
2015
35
Modulation of glucocorticoid resistance in pediatric T-cell Acute Lymphoblastic Leukemia by increasing BIM expression with the PI3K/mTOR inhibitor BEZ235. ( 26080839 )
2015
36
Glucocorticoid resistance in dialysis patients reduces long-term graft survival after kidney transplantation. ( 24746801 )
2014
37
Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance. ( 25193702 )
2014
38
Rheumatoid arthritis--a neuroendocrine immune disorder: glucocorticoid resistance, relative glucocorticoid deficiency, low-dose glucocorticoid therapy, and insulin resistance. ( 25611004 )
2014
39
A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities. ( 24483153 )
2014
40
Lymphocyte sensitivity assay as a marker for glucocorticoid resistance in lupus: report of two sisters with systemic lupus erythematosus. ( 24285097 )
2014
41
Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia. ( 24456076 )
2014
42
Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia. ( 25090024 )
2014
43
Molecular Mechanisms of Repeated Social Defeat-Induced Glucocorticoid Resistance: Role of microRNA. ( 25317829 )
2014
44
Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. ( 24895125 )
2014
45
Serum amyloid A inhibits dendritic cell apoptosis to induce glucocorticoid resistance in CD4(+) T cells. ( 24008730 )
2013
46
Septic serum induces glucocorticoid resistance and modifies the expression of glucocorticoid isoforms receptors: a prospective cohort study and in vitro experimental assay. ( 23759144 )
2013
47
Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor. ( 23611130 )
2013
48
Lack of association between NR3C1 polymorphism and glucocorticoid resistance in Chinese patients with immune thrombocytopenia. ( 23527567 )
2013
49
Immune dysregulation and glucocorticoid resistance in minority and low income pregnant women. ( 23541234 )
2013
50
A novel point mutation in the DNA-binding domain (DBD) of the human glucocorticoid receptor causes primary generalized glucocorticoid resistance by disrupting the hydrophobic structure of its DBD. ( 23426617 )
2013

Variations for Glucocorticoid Resistance

UniProtKB/Swiss-Prot genetic disease variations for Glucocorticoid Resistance:

66 (show all 12)
id Symbol AA change Variation ID SNP ID
1 NR3C1 p.Asp641Val VAR_004676 rs104893908
2 NR3C1 p.Val729Ile VAR_004677
3 NR3C1 p.Arg477His VAR_013472 rs104893913
4 NR3C1 p.Gly679Ser VAR_013473 rs104893914
5 NR3C1 p.Ile559Asn VAR_015632 rs104893909
6 NR3C1 p.Ile747Met VAR_015633 rs104893910
7 NR3C1 p.Phe737Leu VAR_071935 rs121909727
8 NR3C1 p.Leu773Pro VAR_071936 rs104893912
9 NR3C1 p.Thr556Ile VAR_075800
10 NR3C1 p.Arg477Ser VAR_077143
11 NR3C1 p.Tyr478Cys VAR_077144
12 NR3C1 p.Leu672Pro VAR_077145

ClinVar genetic disease variations for Glucocorticoid Resistance:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 NR3C1 NM_001018077.1(NR3C1): c.1922A> T (p.Asp641Val) single nucleotide variant Pathogenic rs104893908 GRCh37 Chromosome 5, 142675126: 142675126
2 NR3C1 NM_000176.2(NR3C1): c.1891_1892+2delGAGT deletion Pathogenic rs587776832 GRCh38 Chromosome 5, 143298666: 143298669
3 NR3C1 NM_001018077.1(NR3C1): c.1676T> A (p.Ile559Asn) single nucleotide variant Pathogenic rs104893909 GRCh37 Chromosome 5, 142680121: 142680121
4 NR3C1 NM_001018077.1(NR3C1): c.2241T> G (p.Ile747Met) single nucleotide variant Pathogenic rs104893910 GRCh37 Chromosome 5, 142661547: 142661547
5 NR3C1 NM_001018077.1(NR3C1): c.2318T> C (p.Leu773Pro) single nucleotide variant Pathogenic rs104893912 GRCh37 Chromosome 5, 142661470: 142661470
6 NR3C1 NM_001018077.1(NR3C1): c.1430G> A (p.Arg477His) single nucleotide variant Pathogenic rs104893913 GRCh37 Chromosome 5, 142689700: 142689700
7 NR3C1 NM_001018077.1(NR3C1): c.2035G> A (p.Gly679Ser) single nucleotide variant Pathogenic rs104893914 GRCh37 Chromosome 5, 142662279: 142662279
8 NR3C1 NM_001018077.1(NR3C1): c.2209T> C (p.Phe737Leu) single nucleotide variant Pathogenic rs121909727 GRCh37 Chromosome 5, 142661579: 142661579

Expression for Glucocorticoid Resistance

Search GEO for disease gene expression data for Glucocorticoid Resistance.

Pathways for Glucocorticoid Resistance

Pathways related to Glucocorticoid Resistance according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 BCL2 FOS IL10 IL2
2
Show member pathways
12.3 BCL2 FOS IL10 IL2
3
Show member pathways
12.27 BCL2 FOS IL10 IL2
4
Show member pathways
12.26 BCL2 FOS NR3C1
5
Show member pathways
12.2 FOS IL10 IL2
6
Show member pathways
12.03 BCL2 FOS IL10
7
Show member pathways
12.02 BCL2 BCL2A1 FOS IL10
8
Show member pathways
11.95 BCL2 IL10 IL2
9
Show member pathways
11.83 BCL2 FOS IL2
10 11.74 BCL2 FOS IL10
11
Show member pathways
11.7 FOS IL10 IL2
12 11.62 BCL2 FOS IL2
13 11.47 FOS IL10 NR3C1
14 11.39 BCL2 FOS
15 11.31 IL10 IL2
16 11.29 FOS NR3C1
17 11.28 FOS IL2
18 11.25 BCL2 FOS IL2
19 11.24 FOS NR3C1
20 11.17 FKBP5 FOS IL2 NR3C1
21 11.13 FOS NR3C1
22 11.08 IL10 IL2
23 11.05 BCL2 FOS
24 11.04 FOS IL2
25
Show member pathways
11.03 BCL2 IL10 IL2
26 10.97 BCL2 IL10 IL2
27 10.92 BCL2 FOS
29 10.75 BCL2 IL10 IL2
30
Show member pathways
10.72 BCL2A1 FOS IL2 NR3C1

GO Terms for Glucocorticoid Resistance

Biological processes related to Glucocorticoid Resistance according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.61 BCL2 FOS IL10
2 positive regulation of B cell proliferation GO:0030890 9.4 BCL2 IL2
3 T cell differentiation GO:0030217 9.37 BCL2 IL2
4 B cell proliferation GO:0042100 9.32 BCL2 IL10
5 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.26 BCL2 IL2
6 negative regulation of mitotic cell cycle GO:0045930 9.16 BCL2 IL10
7 aging GO:0007568 9.13 BCL2A1 FOS IL10
8 negative regulation of apoptotic process GO:0043066 8.92 BCL2 BCL2A1 IL10 IL2

Molecular functions related to Glucocorticoid Resistance according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.16 NR3C1 NR3C2
2 steroid binding GO:0005496 8.96 NR3C1 NR3C2
3 sequence-specific DNA binding GO:0043565 8.92 BCL2 FOS NR3C1 NR3C2

Sources for Glucocorticoid Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....